These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Level of viral load and antiretroviral resistance after 6 months of non-nucleoside reverse transcriptase inhibitor first-line treatment in HIV-1-infected children in Mali. Germanaud D; Derache A; Traore M; Madec Y; Toure S; Dicko F; Coulibaly H; Traore M; Sylla M; Calvez V; Marcelin AG J Antimicrob Chemother; 2010 Jan; 65(1):118-24. PubMed ID: 19933171 [TBL] [Abstract][Full Text] [Related]
24. Virological efficacy and immunological recovery among Ethiopian HIV-1 infected adults and children. Mulu A; Liebert UG; Maier M BMC Infect Dis; 2014 Jan; 14():28. PubMed ID: 24422906 [TBL] [Abstract][Full Text] [Related]
25. Factors Associated With Early Virological Response in HIV-Infected Individuals Starting Antiretroviral Therapy in Brazil (2014-2015): Results From a Large HIV Surveillance Cohort. Meireles MV; Pascom ARP; Duarte EC J Acquir Immune Defic Syndr; 2018 Aug; 78(4):e19-e27. PubMed ID: 29557856 [TBL] [Abstract][Full Text] [Related]
26. Antiretroviral drug resistance profiles and response to second-line therapy among HIV type 1-infected Ugandan children. Musiime V; Kaudha E; Kayiwa J; Mirembe G; Odera M; Kizito H; Nankya I; Ssali F; Kityo C; Colebunders R; Mugyenyi P AIDS Res Hum Retroviruses; 2013 Mar; 29(3):449-55. PubMed ID: 23308370 [TBL] [Abstract][Full Text] [Related]
27. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study. ; Judd A; Chappell E; Turkova A; Le Coeur S; Noguera-Julian A; Goetghebuer T; Doerholt K; Galli L; Pajkrt D; Marques L; Collins IJ; Gibb DM; González Tome MI; Navarro M; Warszawski J; Königs C; Spoulou V; Prata F; Chiappini E; Naver L; Giaquinto C; Thorne C; Marczynska M; Okhonskaia L; Posfay-Barbe K; Ounchanum P; Techakunakorn P; Kiseleva G; Malyuta R; Volokha A; Ene L; Goodall R PLoS Med; 2018 Jan; 15(1):e1002491. PubMed ID: 29381702 [TBL] [Abstract][Full Text] [Related]
28. HIV-1 drug resistance prevalence, drug susceptibility and variant characterization in the Jacobi Medical Center paediatric cohort, Bronx, NY, USA. de Mulder M; York VA; Wiznia AA; Michaud HA; Nixon DF; Holguin A; Rosenberg MG HIV Med; 2014 Mar; 15(3):135-43. PubMed ID: 24112468 [TBL] [Abstract][Full Text] [Related]
29. Adoption of routine virologic testing and predictors of virologic failure among HIV-infected children on antiretroviral treatment in western Kenya. Kadima J; Patterson E; Mburu M; Blat C; Nyanduko M; Bukusi EA; Cohen C; Oyaro P; Abuogi L PLoS One; 2018; 13(11):e0200242. PubMed ID: 30412576 [TBL] [Abstract][Full Text] [Related]
30. Virological failure and HIV drug resistance among adults living with HIV on second-line antiretroviral therapy in the Asia-Pacific. Ross J; Jiamsakul A; Kumarasamy N; Azwa I; Merati TP; Do CD; Lee MP; Ly PS; Yunihastuti E; Nguyen KV; Ditangco R; Ng OT; Choi JY; Oka S; Sohn AH; Law M HIV Med; 2021 Mar; 22(3):201-211. PubMed ID: 33151020 [TBL] [Abstract][Full Text] [Related]
31. Resistance at virological failure using boosted protease inhibitors versus nonnucleoside reverse transcriptase inhibitors as first-line antiretroviral therapy--implications for sustained efficacy of ART in resource-limited settings. Hill A; McBride A; Sawyer AW; Clumeck N; Gupta RK J Infect Dis; 2013 Jun; 207 Suppl 2():S78-84. PubMed ID: 23687293 [TBL] [Abstract][Full Text] [Related]
32. Drug Resistance Among Adolescents and Young Adults with Virologic Failure of First-Line Antiretroviral Therapy and Response to Second-Line Treatment. Kouamou V; Varyani B; Shamu T; Mapangisana T; Chimbetete C; Mudzviti T; Manasa J; Katzenstein D AIDS Res Hum Retroviruses; 2020 Jul; 36(7):566-573. PubMed ID: 32138527 [TBL] [Abstract][Full Text] [Related]
33. Multisystem impairment in South African adolescents with Perinatally acquired HIV on antiretroviral therapy (ART). Frigati LJ; Brown K; Mahtab S; Githinji L; Gray D; Zühlke L; Nourse P; Stein DJ; Hoare J; Cotton MF; Myer L; Zar HJ J Int AIDS Soc; 2019 Aug; 22(8):e25386. PubMed ID: 31441211 [TBL] [Abstract][Full Text] [Related]
34. Height and timing of growth spurt during puberty in young people living with vertically acquired HIV in Europe and Thailand. European Pregnancy and Paediatric HIV Cohort Collaboration (EPPICC) study group AIDS; 2019 Oct; 33(12):1897-1910. PubMed ID: 31274534 [TBL] [Abstract][Full Text] [Related]
36. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting. Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K; AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097 [TBL] [Abstract][Full Text] [Related]
37. Drug-resistance development differs between HIV-1-infected patients failing first-line antiretroviral therapy containing nonnucleoside reverse transcriptase inhibitors with and without thymidine analogues. Santoro MM; Sabin C; Forbici F; Bansi L; Dunn D; Fearnhill E; Boumis E; Nicastri E; Antinori A; Palamara G; Callegaro A; Francisci D; Zoncada A; Maggiolo F; Zazzi M; Perno CF; Ceccherini-Silberstein F; Mussini C HIV Med; 2013 Oct; 14(9):571-7. PubMed ID: 23668660 [TBL] [Abstract][Full Text] [Related]
38. Virologic response of treatment experienced HIV-infected Ugandan children and adolescents on NNRTI based first-line regimen, previously monitored without viral load. Kibalama Ssemambo P; Nalubega-Mboowa MG; Owora A; Serunjogi R; Kironde S; Nakabuye S; Ssozi F; Nannyonga M; Musoke P; Barlow-Mosha L BMC Pediatr; 2021 Mar; 21(1):139. PubMed ID: 33752636 [TBL] [Abstract][Full Text] [Related]
39. Impact of transmitted HIV-1 drug resistance on the efficacy of first-line antiretroviral therapy with two nucleos(t)ide reverse transcriptase inhibitors plus an integrase inhibitor or a protease inhibitor. Spertilli Raffaelli C; Rossetti B; Paglicci L; Colafigli M; Punzi G; Borghi V; Pecorari M; Santoro MM; Penco G; Antinori A; Zazzi M; De Luca A; Zanelli G J Antimicrob Chemother; 2018 Sep; 73(9):2480-2484. PubMed ID: 29945251 [TBL] [Abstract][Full Text] [Related]
40. Impact of antiretroviral treatment on height evolution of HIV infected children. Traisathit P; Urien S; Le Coeur S; Srirojana S; Akarathum N; Kanjanavanit S; Ngampiyaskul C; Krikajornkitti S; Ngo-Giang-Huong N; Lallemant M; Jourdain G BMC Pediatr; 2019 Aug; 19(1):287. PubMed ID: 31421667 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]